Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep533 | Pituitary and Neuroendocrinology | ECE2021

Improved response to somatostatin analogue (SSA) therapy in acromegaly following treatment pause

Rajan Roby , Bhatt D , Philip S , Graveling AJ , Bashari W , Gurnell M , Abraham P

Background/methodsPatients with uncontrolled acromegaly or receiving high cost medical therapy despite initial treatment, usually transsphenoidal surgery (TSS), were considered for a ¹¹C-methionine PET-CT scan (11C-Met PET-CT). This imaging technique may identify a target for TSS or radiotherapy when MRI appearances are inconclusive1. In preparation, four patients on long-term SSA were taken off treatment 3 months prior to the scan. ...

ea0073yi4 | Young Investigator Awards | ECE2021

Use of 11C-methionine PET-CT scanning to guide management of acromegaly following primary therapy – A pragmatic prioritisation strategy to achieve maximal cost effectiveness

Rajan Roby , Bhatt D , Philip S , Graveling AJ , Kamel M , Olson S , Mckiddie F , Gillett D , Bashari W , Gurnell M , Abraham P

Background11C-methionine (11C-Met) positron emission tomography co-registered with MRI is a new imaging technique used for functioning pituitary adenomas, permitting targeted intervention (Transphenoidal Surgery (TSS) or Radiotherapy)1. The 11C-Met PET-CT scan has been available in our centre since Dec 2016. With limited availability in 2019/2020 (due to cyclotron refurbishment) we re-audited our patients to prioritise th...